β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8<sup>+</sup> T Cells and Undermines Checkpoint Inhibitor Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28819022.
- Also identified by DOI 10.1158/0008-5472.CAN-17-0546 and PMC identifier 5645237.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immune context of tumors has significant prognostic value and is predictive of responsiveness to several forms of therapy, including immunotherapy. We report here that CD8<sup>+</sup> T-cell frequency and functional orientation within the tumor microenvironment is regulated by β<sub>2</sub>-adrenergic receptor (β-AR) signaling in host immune cells. We used three strategies-physiologic (manipulation of ambient thermal environment), pharmacologic (β-blockers), and genetic (β<sub>2</sub>-AR knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models. Reducing β-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment with increased intratumoral frequency of CD8<sup>+</sup> T cells with an effector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an elevated effector CD8<sup>+</sup> T-cell to CD4<sup>+</sup> regulatory T-cell ratio (IFNγ<sup>+</sup>CD8<sup>+</sup>:Treg). Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade. These data highlight the potential of adrenergic stress and norepinephrine-driven β-AR signaling to regulate the immune status of the tumor microenvironment and support the strategic use of clinically available β-blockers in patients to improve responses to immunotherapy. <i>Cancer Res; 77(20); 5639-51. ©2017 AACR</i>.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Immunotherapy
- Mammary Neoplasms, Experimental
- Melanoma, Experimental
- Receptors, Adrenergic, beta-2